Faculty & Staff

Joan Garrett

Assistant Professor

Education/Credentials
  • BA: Ohio University
  • BS: Ohio University
  • PhD: Ohio State University

Contact Information

Peer Reviewed Publications

Display All

Mishra, Rosalin; Alanazi, Samar; Yuan, Long; Solomon, Thomas; Thaker, Tarjani M; Jura, Natalia; Garrett, Joan T 2018. Activating HER3 mutations in breast cancer. Oncotarget, 9 45, 27773-27788

Mishra, Rosalin; Patel, Hima; Alanazi, Samar; Yuan, Long; Garrett, Joan T 2018. HER3 signaling and targeted therapy in cancer. Oncology reviews, 12 1, 355

Yuan, Long; Mishra, Rosalin; Patel, Hima; Abdulsalam, Safnas; Greis, Kenneth D; Kadekaro, Ana Luisa; Merino, Edward J; Garrett, Joan T 2018. Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in Melanoma. Journal of Cancer, 9 24, 4665-4676

Hanker, Ariella B; Garrett, Joan T; Estrada, Mónica Valeria; Moore, Preston D; Ericsson, Paula González; Koch, James P; Langley, Emma; Singh, Sharat; Kim, Phillip S; Frampton, Garrett M; Sanford, Eric; Owens, Philip; Becker, Jennifer; Groseclose, M Reid; Castellino, Stephen; Joensuu, Heikki; Huober, Jens; Brase, Jan C; Majjaj, Samira; Brohée, Sylvain; Venet, David; Brown, David; Baselga, José; Piccart, Martine; Sotiriou, Christos; Arteaga, Carlos L 2017. HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clinical cancer research : an official journal of the American Association for Cancer Research, 23 15, 4323-4334

Mishra, Rosalin; Hanker, Ariella B; Garrett, Joan T 2017. Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget, 8 69, 114371-114392

Schwarz, Luis J; Fox, Emily M; Balko, Justin M; Garrett, Joan T; Kuba, María Gabriela; Estrada, Mónica Valeria; González-Angulo, Ana María; Mills, Gordon B; Red-Brewer, Monica; Mayer, Ingrid A; Abramson, Vandana; Rizzo, Monica; Kelley, Mark C; Meszoely, Ingrid M; Arteaga, Carlos L 2014. LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer. The Journal of clinical investigation, 124 12, 5490-502

Garner, Andrew P; Bialucha, Carl U; Sprague, Elizabeth R; Garrett, Joan T; Sheng, Qing; Li, Sharon; Sineshchekova, Olga; Saxena, Parmita; Sutton, Cammie R; Chen, Dongshu; Chen, Yan; Wang, Huiqin; Liang, Jinsheng; Das, Rita; Mosher, Rebecca; Gu, Jian; Huang, Alan; Haubst, Nicole; Zehetmeier, Carolin; Haberl, Manuela; Elis, Winfried; Kunz, Christian; Heidt, Analeah B; Herlihy, Kara; Murtie, Joshua; Schuller, Alwin; Arteaga, Carlos L; Sellers, William R; Ettenberg, Seth A 2013. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer research, 73 19, 6024-35

Garrett, Joan T; Sutton, Cammie R; Kuba, María Gabriela; Cook, Rebecca S; Arteaga, Carlos L 2013. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clinical cancer research : an official journal of the American Association for Cancer Research, 19 3, 610-9

Garrett, Joan T; Sutton, Cammie R; Kurupi, Richard; Bialucha, Carl Uli; Ettenberg, Seth A; Collins, Scott D; Sheng, Qing; Wallweber, Jerry; Defazio-Eli, Lisa; Arteaga, Carlos L 2013. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110? inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. Cancer research, 73 19, 6013-23

Cook, Rebecca S; Garrett, Joan T; Sánchez, Violeta; Stanford, Jamie C; Young, Christian; Chakrabarty, Anindita; Rinehart, Cammie; Zhang, Yixian; Wu, Yaming; Greenberger, Lee; Horak, Ivan D; Arteaga, Carlos L 2011. ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. Cancer research, 71 11, 3941-51

Garrett, Joan T; Arteaga, Carlos L 2011. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer biology & therapy, 11 9, 793-800

Garrett, Joan T; Chakrabarty, Anindita; Arteaga, Carlos L 2011. Will PI3K pathway inhibitors be effective as single agents in patients with cancer? Oncotarget, 2 12, 1314-21

Garrett, Joan T; Olivares, María Graciela; Rinehart, Cammie; Granja-Ingram, Nara D; Sánchez, Violeta; Chakrabarty, Anindita; Dave, Bhuvanesh; Cook, Rebecca S; Pao, William; McKinely, Eliot; Manning, H C; Chang, Jenny; Arteaga, Carlos L 2011. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proceedings of the National Academy of Sciences of the United States of America, 108 12, 5021-6

Miller, Todd W; Rexer, Brent N; Garrett, Joan T; Arteaga, Carlos L 2011. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast cancer research : BCR, 13 6, 224

Kaumaya, Pravin T P; Foy, Kevin Chu; Garrett, Joan; Rawale, Sharad V; Vicari, Daniele; Thurmond, Jennifer M; Lamb, Tammy; Mani, Aruna; Kane, Yahaira; Balint, Catherine R; Chalupa, Donald; Otterson, Gregory A; Shapiro, Charles L; Fowler, Jeffrey M; Grever, Michael R; Bekaii-Saab, Tanios S; Carson, William E 2009. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 31, 5270-7

Allen, Stephanie D; Garrett, Joan T; Rawale, Sharad V; Jones, Audra L; Phillips, Gary; Forni, Guido; Morris, John C; Oshima, Robert G; Kaumaya, Pravin T P 2007. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo. Journal of immunology (Baltimore, Md. : 1950), 179 1, 472-82

Garrett, Joan T; Rawale, Sharad; Allen, Stephanie D; Phillips, Gary; Forni, Guido; Morris, John C; Kaumaya, Pravin T P 2007. Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu. Journal of immunology (Baltimore, Md. : 1950), 178 11, 7120-31

Dakappagari, Naveen K; Lute, Kenneth D; Rawale, Sharad; Steele, Joan T; Allen, Stephanie D; Phillips, Gary; Reilly, R Todd; Kaumaya, Pravin T P 2005. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities. The Journal of biological chemistry, 280 1, 54-63

Visit the College

Group Photo of the dean and students

See our difference at the James L Winkle College of Pharmacy. We are among the oldest in the nation, with cutting-edge research, excellent scholarship and distinguished faculty. Visit the College to Learn More

Life in Cincinnati

Resting along the banks of the Ohio River, Cincinnati offers something for everyone. From foodies to sports fans, cultural hotspots to family-friendly attractions discover our dynamic city. Learn More about Life in Cincinnati

Photo of a statue